Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.22.4
Segment Information (Tables)
12 Months Ended
Dec. 31, 2022
Disclosure of operating segments [abstract]  
Summary of making decisions regarding the allocation of resources and to assess performance

The criteria applied to identify the operating segments are consistent with the information reviewed by the Chief Executive Officer (the Group’s “Chief Operating Decision Maker”) in making decisions regarding the allocation of resources and to assess performance.

 

 

 

As at and for the year ended December 31, 2022

 

 

 

Biopharmaceutical
and Diagnostic
Solutions

 

 

Engineering

 

 

Total
segments

 

 

Adjustments,
eliminations
and
unallocated
items

 

 

Consolidated

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

799,652

 

 

 

184,028

 

 

 

983,680

 

 

 

 

 

 

983,680

 

Inter-Segment

 

 

1,585

 

 

 

115,472

 

 

 

117,057

 

 

 

(117,057

)

 

 

 

Total Revenue

 

 

801,237

 

 

 

299,500

 

 

 

1,100,737

 

 

 

(117,057

)

 

 

983,680

 

Cost of Sales

 

 

526,370

 

 

 

234,826

 

 

 

761,196

 

 

 

(97,317

)

 

 

663,879

 

Gross Profit

 

 

274,867

 

 

 

64,674

 

 

 

339,541

 

 

 

(19,740

)

 

 

319,801

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other operating income

 

 

18,985

 

 

 

13

 

 

 

18,998

 

 

 

(148

)

 

 

18,850

 

Selling and Marketing expenses

 

 

12,287

 

 

 

2,430

 

 

 

14,717

 

 

 

11,369

 

 

 

26,086

 

Research and Development expenses

 

 

25,169

 

 

 

6,542

 

 

 

31,711

 

 

 

2,676

 

 

 

34,387

 

General and Administrative expenses

 

 

73,816

 

 

 

14,431

 

 

 

88,247

 

 

 

(2,500

)

 

 

85,747

 

Operating Profit

 

 

182,580

 

 

 

41,284

 

 

 

223,864

 

 

 

(31,433

)

 

 

192,431

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

1,259,124

 

 

 

370,851

 

 

 

1,629,975

 

 

 

29,723

 

 

 

1,659,698

 

Total liabilities

 

 

511,022

 

 

 

256,835

 

 

 

767,857

 

 

 

(104,069

)

 

 

663,788

 

 

 

 

As at and for the year ended December 31, 2021

 

 

 

Biopharmaceutical
and Diagnostic
Solutions

 

 

Engineering

 

 

Total
segments

 

 

Adjustments,
eliminations
and
unallocated
items

 

 

Consolidated

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

694,038

 

 

 

149,882

 

 

 

843,920

 

 

 

 

 

 

843,920

 

Inter-Segment

 

 

1,134

 

 

 

68,979

 

 

 

70,113

 

 

 

(70,113

)

 

 

 

Total Revenue

 

 

695,172

 

 

 

218,861

 

 

 

914,033

 

 

 

(70,113

)

 

 

843,920

 

Cost of Sales

 

 

465,304

 

 

 

176,604

 

 

 

641,908

 

 

 

(63,393

)

 

 

578,515

 

Gross Profit

 

 

229,868

 

 

 

42,257

 

 

 

272,125

 

 

 

(6,720

)

 

 

265,405

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other operating income

 

 

9,386

 

 

 

 

 

 

9,386

 

 

 

 

 

 

9,386

 

Selling and Marketing expenses

 

 

7,736

 

 

 

3,196

 

 

 

10,932

 

 

 

9,516

 

 

 

20,448

 

Research and Development expenses

 

 

23,467

 

 

 

4,263

 

 

 

27,730

 

 

 

1,886

 

 

 

29,616

 

General and Administrative expenses

 

 

58,996

 

 

 

11,898

 

 

 

70,894

 

 

 

(8,392

)

 

 

62,502

 

Operating Profit

 

 

149,055

 

 

 

22,900

 

 

 

171,955

 

 

 

(9,730

)

 

 

162,225

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

885,733

 

 

 

253,767

 

 

 

1,139,500

 

 

 

279,342

 

 

 

1,418,842

 

Total liabilities

 

 

335,919

 

 

 

163,661

 

 

 

499,580

 

 

 

77,603

 

 

 

577,183

 

 

 

 

 

As at and for the year ended December 31, 2020

 

 

 

Biopharmaceutical
and Diagnostic
Solutions

 

 

Engineering

 

 

Total
segments

 

 

Adjustments,
eliminations
and
unallocated
items

 

 

Consolidated

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

564,931

 

 

 

97,106

 

 

 

662,037

 

 

 

 

 

 

662,037

 

Inter-Segment

 

 

1,096

 

 

 

56,327

 

 

 

57,423

 

 

 

(57,423

)

 

 

 

Total Revenue

 

 

566,027

 

 

 

153,433

 

 

 

719,460

 

 

 

(57,423

)

 

 

662,037

 

Cost of Sales

 

 

398,411

 

 

 

121,332

 

 

 

519,743

 

 

 

(51,882

)

 

 

467,861

 

Gross Profit

 

 

167,616

 

 

 

32,101

 

 

 

199,717

 

 

 

(5,541

)

 

 

194,176

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other operating income

 

 

5,193

 

 

 

31

 

 

 

5,224

 

 

 

7

 

 

 

5,230

 

Selling and Marketing expenses

 

 

9,762

 

 

 

2,842

 

 

 

12,604

 

 

 

7,440

 

 

 

20,044

 

Research and Development expenses

 

 

12,080

 

 

 

3,056

 

 

 

15,136

 

 

 

2,254

 

 

 

17,390

 

General and Administrative expenses

 

 

48,324

 

 

 

9,641

 

 

 

57,965

 

 

 

899

 

 

 

58,863

 

Operating Profit

 

 

102,643

 

 

 

16,593

 

 

 

119,236

 

 

 

(16,127

)

 

 

103,109

 

 

Reconciliation from Segments Operating Profit to Consolidated Profit before Tax Explanatory

The reconciliation from total segments Operating Profit to consolidated Profit Before Tax is as follows:

 

 

For the year ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

 

 

(EUR thousand)

 

Segments Operating Profit

 

 

223,864

 

 

 

171,955

 

 

 

119,236

 

Finance income

 

 

25,050

 

 

 

21,709

 

 

 

14,926

 

Finance expense

 

 

29,840

 

 

 

18,808

 

 

 

21,848

 

Share of profit of an associate

 

 

 

 

 

547

 

 

 

92

 

Inter-segment elimination

 

 

(31,433

)

 

 

(9,730

)

 

 

(16,127

)

Profit Before Tax

 

 

187,641

 

 

 

165,673

 

 

 

96,279